Education
About Us
Working with TipRanks
Follow Us
Cabaletta Bio, Inc. (CABA)
:CABA
CABA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.99 - $6.26
Previous CloseN/A
Volume846.62K
Average Volume (3M)1.47M
Market Cap
$139.41M
Enterprise Value-$34.41M
Total Cash (Recent Filing)$131.83M
Total Debt (Recent Filing)$28.79M
Price to Earnings (P/E)―
Beta3.91
Next Earnings
Nov 12, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding89,943,100
10 Day Avg. Volume887,701
30 Day Avg. Volume1,468,643
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit80.78
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$15.29Price Target Upside919.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Efficacy And Safety DataPromising initial efficacy and safety data from myositis, lupus, and scleroderma cohorts solidify Cabaletta's position as a leader in developing cell therapy for autoimmune disease.
Financial StabilityThe raise removes the near-term financial overhang and likely extends runway beyond the prior guidance.
Regulatory ProgressRecent FDA alignment on a registrational pathway for rese-cel clarifies the path to market in myositis.
Bears Say
Depth Of Response UncertaintyClinical responses were achieved across all myositis subtypes with rese-cel, but depth of responses in IMNM is unclear.
Financing ConcernsThe proposed offering at depressed levels versus other financing options isn't a good sign.
Stock Offering ImpactCabaletta announced a $100M stock offering, which has pressured shares given meaningful dilution.
Cabaletta Bio News
CABA FAQ
What was Cabaletta Bio, Inc.’s price range in the past 12 months?
Cabaletta Bio, Inc. lowest stock price was $0.98 and its highest was $6.26 in the past 12 months.
What is Cabaletta Bio, Inc.’s market cap?
Cabaletta Bio, Inc.’s market cap is $139.41M.
When is Cabaletta Bio, Inc.’s upcoming earnings report date?
Cabaletta Bio, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 96 days.
How were Cabaletta Bio, Inc.’s earnings last quarter?
Cabaletta Bio, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.08.
Is Cabaletta Bio, Inc. overvalued?
According to Wall Street analysts Cabaletta Bio, Inc.’s price is currently Undervalued.
Does Cabaletta Bio, Inc. pay dividends?
Cabaletta Bio, Inc. does not currently pay dividends.
What is Cabaletta Bio, Inc.’s EPS estimate?
Cabaletta Bio, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Cabaletta Bio, Inc. have?
Cabaletta Bio, Inc. has 89,943,100 shares outstanding.
What happened to Cabaletta Bio, Inc.’s price movement after its last earnings report?
Cabaletta Bio, Inc. reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went down -1.515%.
Which hedge fund is a major shareholder of Cabaletta Bio, Inc.?
Currently, no hedge funds are holding shares in CABA
Cabaletta Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.29 (919.33% Upside)
$15.29 (919.33% Upside)
Blogger Sentiment
Neutral
CABA Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 23.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.79%
12-Months-Change
Fundamentals
Return on Equity
-73.85%
Trailing 12-Months
Asset Growth
-31.32%
Trailing 12-Months
Company Description
Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
CABA Stock 12 Month Forecast
Average Price Target
$15.29
▲(919.33% Upside)
Technical Analysis
Cassava Sciences
―
VistaGen Therapeutics
―
vTv Therapeutics
―
Renovaro Biosciences
―
Jasper Therapeutics
―
Ownership Overview
1.74%
Insiders
9.68% Mutual Funds
0.01% Other Institutional Investors
85.53% Public Companies and
Individual Investors